You are required to be logged in to access the full website
Click here if you have forgotten your username or password
Therapy Areas
23 June 2025 - Merck & Co, Inc (NYSE: MRK), a research-intensive biopharmaceutical company, announced on Monday that its Phase 3 HYPERION study evaluating WINREVAIR (sotatercept-csrk) in adults recently diagnosed with pulmonary arterial hypertens...
23 June 2025 - Biotechnology company Alvotech SA (NASDAQ:ALVO) announced on Monday that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion recommending marketing authorisation for AVT06, ...
23 June 2025 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) announced on Monday that the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) has issued a positive opinion recommending the a...
23 June 2025 - Halozyme Therapeutics Inc (NASDAQ:HALO) announced on Friday that Dutch immunology company argenx SE (Euronext Brussels:ARGX) (Nasdaq:ARGX) has received European Commission approval for VYVGART 1000mg (efgartigimod alfa) developed with ...
23 June 2025 - Chinese pharmaceutical company Gan & Lee Pharmaceuticals (SH:603087) announced on Saturday that it presented multiple Phase 2 clinical study results of ultra-long-acting GLP-1 receptor agonist (GLP-1 RA) bofanglutide (research code...
23 June 2025 - China-based global biopharmaceutical company Harbour BioMed (HKEX: 02142) announced on Sunday a global strategic collaboration with Japan's Otsuka Pharmaceutical Co Ltd to advance BCMAxCD3 bispecific T-cell engagers for the treatm...
20 June 2025 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) announced on Friday that the US Food and Drug Administration has approved Dupixent (dupilumab) as the first targeted treatment for adult patients with bullous pemp...